FDA Issues Draft Guides for Generic Drug Approvals
Published Date: 12/5/2025
Notice
Summary
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by February 3, 2026, before these guides become final. These updates aim to speed up drug approvals and keep costs down for everyone.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Draft guidances for generic drug studies
If you make generic drugs, the FDA posted new draft and revised draft product-specific guidances that give recommendations on how to design bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). The notice lists specific active ingredients covered (see Tables 1 and 2) and these guidances are available on FDA's website.
FDA says updates aim to speed approvals
The notice states these updates aim to speed up drug approvals and keep costs down for everyone. If that occurs, consumers could see faster availability of generic drugs and lower drug costs.
Opportunity to comment by Feb 3, 2026
You may submit electronic or written comments on these draft guidances; to ensure the FDA considers your input before it begins work on the final version, submit comments by February 3, 2026. Instructions for electronic and paper submissions and how to submit confidential material are provided in the notice.
Guidances are non-binding; alternatives allowed
The draft guidances represent the FDA's current thinking but do not establish rights and are not binding. You may use an alternative approach if it satisfies applicable statutes and regulations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2025-22129 — Sunshine Act Meeting Notice
The Federal Trade Commission is holding a secret meeting on December 9, 2025, to discuss a law enforcement issue. This meeting is closed to the public, so no one outside the Commission will hear the details. It affects anyone interested in FTC actions but doesn’t signal any immediate money changes or public deadlines.
Next: 2025-22132 — National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is holding a virtual meeting on January 13-14, 2026, to review research progress and discuss grant applications. Scientists, researchers, and grant applicants will be affected as some sessions are open to the public while others are private to protect personal info. This meeting helps decide funding and research directions but doesn’t announce new money or deadlines yet.